Organovo (ONVO) Stock Price, News & Analysis

Company Overview

Organovo Holdings, Inc. (NASDAQ:ONVO) is a biotechnology company specializing in three-dimensional (3D) bioprinting technology to create functional human tissues for medical research and therapeutic applications. Founded in 2007 and headquartered in San Diego, California, Organovo develops living tissue models that closely mimic the structure and function of human organs. These tissue models are designed to accelerate drug discovery, reduce animal testing, and support regenerative medicine programs.

The company’s core offering is its proprietary NovoGen Bioprinter platform, which layers living cells and biomaterials to fabricate 3D human tissue structures. Organovo’s exVive Human Liver Tissue is one of its lead commercial products, providing pharmaceutical companies with a tool for assessing drug toxicity and efficacy in a biologically relevant setting. The firm is also advancing research initiatives in oncology, kidney disease and other therapeutic areas by developing tumor models and kidney tissues that support disease modeling and drug screening.

Organovo serves clients in the pharmaceutical, biotechnology and academic research sectors across North America, Europe and Asia. Through collaborations and service agreements, the company partners with leading drug developers and research institutions to customize tissue models for specific programs. Its contract research services include assay development, pathway analysis and long-term tissue maintenance, supporting preclinical and translational research workflows.

The company’s leadership team brings expertise in biotechnology, engineering and clinical research. Organovo is led by Chief Executive Officer Kevin Mills, who has guided the company’s strategic focus on commercial tissue products and partnerships since 2019. The executive team and board of directors feature veteran professionals with backgrounds in drug development, regulatory affairs and biomedical instrumentation, positioning Organovo to advance the adoption of bioprinted tissues in both research and therapeutic contexts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.66 to $15.24
• 52-Week Range: N/A
• Volume: 243,634 shs
• Average Volume: 617,505 shs
• Market Capitalization: $3.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ONVO Stock Analysis - Frequently Asked Questions

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) issued its earnings results on Wednesday, February, 19th. The medical research company reported ($2.28) earnings per share for the quarter, topping the consensus estimate of ($2.52) by $0.24. The medical research company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. Organovo had a negative trailing twelve-month return on equity of 346.26% and a negative net margin of 10,151.64%.

When did Organovo's stock split?

Organovo shares reverse split on Friday, March 21st 2025.The 1-12 reverse split was announced on Wednesday, March 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What other stocks do shareholders of Organovo own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organovo investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), Brainstorm Cell Therapeutics (BCLI), AST SpaceMobile (ASTS) and Virgin Galactic (SPCE).

Company Calendar

• Last Earnings: 2/19/2025
• Today: 7/17/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONVO
• CIK: 1497253
• Web: www.organovo.com
• Phone: (858) 224-1000
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($10.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.67 million
• Net Margins: -10,151.64%
• Pretax Margin: -10,150.00%
• Return on Equity: -346.26%
• Return on Assets: -187.53%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.72
• Quick Ratio: 1.72

Sales & Book Value

• Annual Sales: $122 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,701,000
• Free Float: 14,794,000
• Market Cap: $3.47 million
• Optionable: Optionable
• Beta: 1.13